Pharma at war with Azar?

  • After reporting a 45% increase in quarterly profit Pfizer said “it’s business as normal”.
  • Drug companies have made clear that they’ll never voluntarily reduce prices.
  • The pharma industry has spent more than $216 million on lobbying this year.
  • “Telling companies to voluntarily lower their prices and expecting it to happen on a consistent basis is not a realistic long-term policy proposition,” said Anthony T. LoSasso, a professor of health policy and administration at the University of Illinois at Chicago.

Continue reading